Obama Orders FDA to Zero In on Drug Shortage Crisis - page 2
...President Obama called for swift government action Monday against a drug shortage crisis that's increasingly left doctors and hospitals scrambling for life-saving medications -- often including... Read More
Nov 8, '11Quote from KyrshamarksNo, but it can force said company, via tax laws, to leave America altogether, thus creating unemployed Americans.The government cannot force a company to make a product if it does not want to.
It can force Americans to get shot full of radiation at the airport.
It can spray chem trails, filling our air and food-growing soil and food-yielding waterways with barium, aluminum, and other metals.
It can dictate what our kids learn in public schools, even in home schools or church-run schools.
And let's not even start on forcing people to get vaccinated.
Where's the justice?
Nov 8, '11Quote from UnionRN2My local alternative paper had an article about drug shortages in September.Years ago when I worked in a pharmacy the pharmacist showed me an article in a journal from a pharmacy organization he belonged to. Basically it said that company A had bought all the raw ingredients needed by Company B to put out a certain drug. Company A didn't need the ingredients for their product, they were just holding on to it so that their competing product would gain an edge in sales. Company B took company A to court after failed negotiations. Company A destroyed the stash of the raw materials.
I wonder how much of this is still going on and contributing to the shortages. And it makes me wonder how many of these shortages are done on purpose to drive up the prices and put more money in the pockets of those CEOs of the drug companies.
What's causing the drug shortages currently plaguing America's hospitals? Quality problems, including potentially deadly microbial contamination, caused more than half of the recent shortages in injectable drugs, according to the FDA. Other factors impacting the supply chain, according to government and nonprofit researchers, as well as pharmaceutical trade publications, include: cost-cutting manufacture, lack of raw ingredients, just-in-time production, Medicare price controls, discontinuation of less lucrative products, domestic and foreign outsourcing, substandard ingredients, and so-called "pay to delay" deals, in which makers of brand-name drugs with patents about to expire pay generic drug makers to delay marketing of generic versions.